Ambrohexal, 6 mg/ml syrup 100 ml

Pharmacodynamics
Has secretomotor, secretolytic and expectorant action, stimulates serous glandular cells of the bronchial mucosa, increases the mucous secretion and release of surfactant (surfactant) in the alveoli and bronchi, normalizes the disturbed ratio of serous and mucous components of sputum.

By activating hydrolyzing enzymes and increasing the release of lysosomes from the clara cells, reduces the viscosity of sputum. Increases the motor activity of the atrial epithelium, increases mucociliary transport, facilitates the expulsion of sputum from the airways.

On average, the effect when ambroxol is taken orally occurs within 30 minutes and lasts 6-12 hours, depending on the size of the single dose.

Pharmacokinetics

Ambroxol after oral administration is quickly and almost completely absorbed.
Time to maximum concentration (TSmax) after oral administration is reached after 1-3 hours.
Metabolized in the liver with the formation of metabolites, excreted through the kidneys (dibromanthranilic acid, glucuronides).

Binding with blood plasma proteins is approximately 85%.

Half-life period (T1/2) from blood plasma is 7-12 hours. T1/2 of ambroxol and its metabolites is approximately 22 hours. Through the kidneys 90% of ambroxol is excreted in the form of metabolites. Less than 10% of ambroxol is excreted unchanged through the kidneys.

Due to high protein binding and large volume of distribution, as well as slow reverse penetration from tissues into blood, during dialysis or forced diuresis there is no significant ambroxol excretion. Ambroxol clearance in patients with severe hepatic impairment is reduced by 20-40%.

In severe renal failure half-life of ambroxol metabolites is increased. Ambroxol penetrates through the placental barrier and into the breast milk.

Indications

Acute and chronic respiratory diseases accompanied by viscous secretion:

Active ingredient

Composition

5 ml of syrup contains:

The active ingredient:

ambroxol hydrochloride 15 mg;

Excipients:

benzoic acid;

citric acid;

glycerin;

sodium cyclamate;

sodium hydroxide;

sodium metabisulfite;

polyvidone; sorbitol;

purified water;

flavorings.

How to take, the dosage

Interaction

Concomitant use with anti-cough drugs leads to difficulty of expectoration of sputum against the background of suppression of the cough reflex. It increases penetration into the bronchial secretion of amoxicillin, cefuroxime, erythromycin and doxycycline.

Special Instructions

Ambroxol should not be taken simultaneously with anti-cough medications that may inhibit the cough reflex, such as codeine, because this may make it difficult to remove liquefied sputum from the airways. Ambrohexal® should be used with caution in patients with an impaired cough reflex or impaired mucociliary transport because of the potential for sputum accumulation.

Patients taking ambroxol should not be advised to perform breathing exercises; aspiration of diluted sputum should be performed in severely ill patients.

In patients with bronchial asthma, ambroxol may increase coughing.

Ambroxol should not be taken immediately before bedtime.

Please note for diabetics: 1 scoop (5 ml syrup) contains 1.75 g sorbitol (less than 0.15 IU).

Contraindications

Hypersensitivity to ambroxol and other components of the drug forms.

Side effects

Overdose

Symptoms: nausea, vomiting, gastralgia. There are reports of the occurrence of transient restlessness and diarrhea. In severe overdose there may be a drop in blood pressure.

Treatment: induction of vomiting, gastric lavage during the first 1-2 hours after taking the drug, prescription of fat-containing products.

Pregnancy use

Similarities